0001551986-20-000221.txt : 20200708 0001551986-20-000221.hdr.sgml : 20200708 20200708162934 ACCESSION NUMBER: 0001551986-20-000221 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200706 FILED AS OF DATE: 20200708 DATE AS OF CHANGE: 20200708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Darvish Nissim CENTRAL INDEX KEY: 0001793602 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37797 FILM NUMBER: 201018659 MAIL ADDRESS: STREET 1: C/O INNOVATE BIOPHARMACEUTICALS, INC. STREET 2: 8480 HONEYCUTT ROAD, SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC. CENTRAL INDEX KEY: 0001551986 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273948465 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 8480 HONEYCUTT ROAD STREET 2: SUITE 120 CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Monster Digital, Inc. DATE OF NAME CHANGE: 20150930 FORMER COMPANY: FORMER CONFORMED NAME: Tandon Digital, Inc. DATE OF NAME CHANGE: 20120611 4 1 wf-form4_159424015969483.xml FORM 4 X0306 4 2020-07-06 0 0001551986 9 METERS BIOPHARMA, INC. NMTR 0001793602 Darvish Nissim C/O 9 METERS BIOPHARMA, INC. 8480 HONEYCUTT RD, STE 120 RALEIGH NC 27615 1 0 1 0 Stock Option (Right to Buy) 0.6216 2020-07-06 4 A 0 100000 0 A 2030-07-06 Common stock 100000.0 100000 I see footnote The option shall vest in 36 equal monthly installments beginning July 6, 2020. The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned indirectly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. /s/ Donald R. Reynolds, as power of attorney 2020-07-08